Articles from Verge Genomics

— Lilly to Develop Two Targets Identified and Validated Using Verge Genomics’ AI-Enabled, All-in-Human CONVERGE® Platform

VRG50635 is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, announced today that Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference, on Wednesday, February 28th from 10:45 a.m. – 11:15 a.m. EST.

VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, announced today that Verge Genomics’ co-founder and CEO, Alice Zhang, will present at the 42nd Annual J.P. Morgan Healthcare Conference. Alice will provide an overview of Verge and recent corporate milestones on Thursday, January 11th, at 11:30 AM PT in the Golden Gate room (32nd Floor) of The Westin Hotel in San Francisco, CA.

Modality’s multimodal AI platform will capture critical speech and language changes

Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced the completion of the Phase 1 clinical trial of VRG50635 in healthy adult volunteers. VRG50635 was dosed up to the maximum single and repeated doses planned, demonstrating a favorable safety, tolerability, and pharmacokinetic profile supportive of advancement into a proof-of-concept study in people with amyotrophic lateral sclerosis (ALS). Detailed results from the study will be presented at the upcoming European Network to Cure ALS (ENCALS) 2023 meeting being held in Barcelona, Spain from July 12-14, 2023.

Verge Genomics, a clinical-stage, biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Robert H. Scannevin, Ph.D., Chief Scientific Officer, will join other experts in a panel discussion regarding the latest trends in brain health, at the Mass General Brigham and Bank of America World Medical Innovation Forum in Boston on June 12, 2023.

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery and development, announced that Emerald Innovations’ wireless digital health technology will be used to capture critical patient data in its planned Phase 1b proof-of-concept study of the PIKfyve inhibitor VRG50635, a novel therapeutic in clinical development for amyotrophic lateral sclerosis (ALS).

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced that Alice Zhang, CEO and co-founder of Verge Genomics, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:30 AM (PT).

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer. Dr. Cadavid will lead clinical development for Verge, including the company’s recently-initiated Phase 1 trial of VRG50635, a novel therapeutic for amyotrophic lateral sclerosis (ALS) discovered from its CONVERGE™ platform.

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that Alice Zhang, CEO and co-founder of Verge Genomics, will present at both the Piper Sandler 34th Annual Healthcare Conference on November 29 in New York, and the 5th Annual Evercore ISI HealthCONx Conference 2022 on November 30. Please see additional information below:

Verge Genomics, a clinical-stage, tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs for complex diseases, announced today that Alice Zhang, CEO and co-founder of Verge Genomics, has been named to both Fortune’s 2022 40 Under 40 list of rising business influencers and Fierce Biotech’s list of the 2022 Fiercest Women in Life Sciences.

Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform drug discovery, announced today that the first subject has been dosed in a Phase 1 clinical trial of VRG50635. VRG50635 is a small molecule inhibitor of PIKfyve, a novel therapeutic target for amyotrophic lateral sclerosis (ALS) discovered by CONVERGETM, Verge’s all-in-human, AI-powered platform.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that John Applegate will join the company as Chief Financial Officer.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Goldman Sachs (NYSE:GS) is recognizing Verge’s Chief Executive Officer and co-founder, Alice Zhang, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Fierce Biotech named it as a 2022 “Fierce 15” recipient, a recognition given to the biopharmaceutical industry’s most promising early-stage companies.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today that Alfred W. Sandrock, Jr., M.D., Ph.D., has been appointed to its Board of Directors.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11th at 4:30 p.m. EST. Co-founder and CEO Alice Zhang will provide an overview of Verge and recent pipeline and corporate milestones.

Verge Genomics, a tech-enabled drug discovery company pioneering the use of artificial intelligence (AI) and human data to develop new drugs, announced today it has closed an oversubscribed $98 million equity financing. The Series B financing was led by funds managed by BlackRock and supported by new healthcare and technology investors, including Eli Lilly and Company, Merck Global Health Innovation Fund (Merck GHI), Section 32, and Vulcan Capital, alongside Verge’s existing investors, including Threshold Ventures, ALS Investment Fund, Tao Capital Partners, Lifeforce Capital, and others.

Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, announced today that Andrew Allen, M.D., Ph.D., President and Chief Executive Officer at Gritstone bio, has been appointed as an Independent Director to its Board of Directors. Well versed in shepherding companies from discovery through preclinical and clinical development, Dr. Allen brings the skills and perspective necessary to help the company drive growth.

Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, today announced a three-year collaboration with Eli Lilly and Company to research and develop novel therapies for the treatment of amyotrophic lateral sclerosis (ALS), a devastating motor neuron disease.

Verge Genomics, a biotech company that has created an industry leading all-in-human, artificial-intelligence-powered drug discovery and development platform focused on therapies for serious genetic diseases, today announced that data from preclinical studies using its novel PIKfyve inhibitor VRG101 showed broad spectrum of antiviral activity. The results will be presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) online meeting being held July 9-12, 2021.

Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Mario Saltarelli, M.D., Ph.D., CEO of U.S. Green Valley Pharmaceuticals, has been appointed to Verge’s Scientific Advisory Board. Dr. Saltarelli is a neurologist, drug developer, and entrepreneur with more than 30 years of leadership experience in the biopharmaceutical sector, spanning all areas of pharmaceutical and regulatory science, from preclinical through post-market development with an emphasis on neurological diseases and rare autoimmune diseases.